📢 The next era of HIV care: What’s shaping treatment? At EACS 2025, Dr Monica Gandhi highlighted the major shifts redefining HIV management — from simplified once-daily regimens to emerging long-acting approaches designed to support lifelong adherence and individualised care.

💡Is pharma for you? Whether you’re coming from agency life, a clinical role or academia, many HCPs wonder what lies behind the doors of the pharmaceutical industry. In this episode, we talk to Sian Kneller, Founder of The Agency Advantage. With over 20 years’ experience—from

🤖 AI and Machine Learning in HIV Prevention and Care A new narrative review explores how artificial intelligence and machine learning are being applied across the HIV care continuum—from enhancing prevention strategies and early diagnosis to optimising treatment and supporting

🌍 Disruptions to the US Research Landscape: What It Means for Global Health Our latest editorial examines the sweeping research funding cuts and dismantled international partnerships introduced in early 2025 by the new US administration. The article explores: 🔹Recent global

🧠 Plasma Biomarkers and Cognitive Decline in HIV: What Recent Evidence Shows As the population of older people living with HIV continues to rise, understanding cognitive decline has become increasingly important. Our latest article reviews findings from two major US cohorts,

🩺 On the Spot: Point-of-Care Testing for STIs Rising STI rates are a growing global concern. In this episode of Visionary Voices, Dr Libby van Gerwen explains how point-of-care testing is helping clinicians identify and manage infections more quickly, improving patient

🔬 Future Leader Spotlight: Dr Ikechukwu Benjamin Moses “Bacteriophage therapy may be the next big step in reducing antibiotic dependence.” Dr Moses, winner of the Emerging Young Investigator Award at ESCMID Global 2025, is exploring how AI, genomic sequencing, and phage gene

🤖 AI and Machine Learning in HIV Prevention and Care A new narrative review explores how artificial intelligence and machine learning are being applied across the HIV care continuum—from enhancing prevention strategies and early diagnosis to optimising treatment and supporting

🦟 Chikungunya milestone: First FDA-approved vaccine for teens & adults The FDA has approved the first virus-like particle (VLP) chikungunya vaccine for individuals aged 12 years and older — addressing a critical unmet need in preventing this mosquito-borne disease. 🌍

🧬 Evidence leads the way in HIV care As we observe World AIDS Day 2025, we are reminded that rebuilding the HIV response requires protecting scientific freedom and ensuring evidence guides our policies. The @iasociety emphasizes the need for a resilient HIV response that rises

🧩 Optimising Hepatitis C Treatment and Management Despite the availability of highly effective therapies, hepatitis C virus (HCV) remains a major public health challenge — with diagnosis and reinfection posing key barriers to elimination. In this expert Q&A, Prof. Christoph

🌍 World AIDS Day 2025: Rethink. Rebuild. Rise. Today, we join our media partner @iasociety and the global HIV community to mark World AIDS Day 2025. A moment to reflect, recommit and act so that no one is left behind. This year’s theme – Rethink. Rebuild. Rise. – calls on all

🧪 Long-term HIV Treatment Outcomes New research presented at IAS 2025 shows that switching to an alternative antiretroviral regimen can maintain viral suppression while improving certain cardiometabolic markers. Findings included: ✅ Sustained efficacy over 96 weeks ✅ Lower

💉 “An HIV vaccine wouldn’t just save lives – it would transform entire communities.” Dr Amesika Nyaku (Northwestern University) explores the scientific challenges, breakthroughs and global significance of HIV vaccine development. 🔬 From mRNA to broadly neutralising

🌍 Disruptions to the US Research Landscape: What It Means for Global Health Our latest editorial examines the sweeping research funding cuts and dismantled international partnerships introduced in early 2025 by the new US administration. The article explores: 🔹Recent global

🧠 Plasma Biomarkers and Cognitive Decline in HIV: What Recent Evidence Shows As the population of older people living with HIV continues to rise, understanding cognitive decline has become increasingly important. Our latest article reviews findings from two major US cohorts,

📢 touchREVIEWS in Infectious Diseases – Volume 4, Issue 1, 2025 Welcome to the 2025 issue of touchREVIEWS in Infectious Diseases! This edition features insightful editorials and review articles covering key topics such as COVID-19, HIV, and viral infections. A huge thank you

🩺 Prescribe smart. Protect futures. Every prescription is an opportunity to slow antimicrobial resistance and safeguard the effectiveness of antibiotics for generations to come. Whether in hospitals, clinics, or community settings, responsible prescribing is a shared

🧫 Overusing and misusing antibiotics puts everyone at risk. In humans, overuse can lead to drug-resistant harmful bacteria and disrupt beneficial microbes that support our health. When patients attend hospitals or clinics, drug-resistant bacteria can spread through poor hygiene

📢 Once-monthly PrEP? Promising early data presented at IAS 2025 Prof. Kenneth Mayer (Harvard Medical School; Fenway Health) shared encouraging results on a new oral PrEP option being studied for monthly use. Designed for people who may not prefer daily pills or injections, this